GLYX 13 – 5 mg

Brand:
Cayman
CAS:
117928-94-6
Storage:
-20
UN-No:
Non-Hazardous - /

GLYX 13 is a monoclonal antibody-derived tetrapeptide that acts as a partial agonist at the glycine site of the N-methyl-D-aspartate (NMDA) receptor.{33821,33823} It is active in vivo when administered intravenously, and it readily passes through the blood-brain barrier.{33821,33818} GLYX 13 has diverse effects in animals, as it blocks neuropathic pain, enhances learning and memory, and significantly reduces anxiety.{33823,33818,33820} GLYX 13 induces rapid antidepressant-like effects in animal models and rescued normal behavior in a rat model of autism.{33819,33822,33824}  

 

Out of stock

SKU: 21385 - Category:

Description

A monoclonal antibody-derived tetrapeptide that acts as a partial agonist at the glycine site of the NMDA receptor; active in vivo and readily passes the BBB; blocks neuropathic pain, enhances learning and memory, and significantly reduces anxiety in animals


Formal name: L-threonyl-L-prolyl-L-prolyl-L-threoninamide

Synonyms:  Rapastinel

Molecular weight: 413.5

CAS: 117928-94-6

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Ion Channel Modulation|Activators||Research Area|Neuroscience|Behavioral Neuroscience|Anxiety||Research Area|Neuroscience|Behavioral Neuroscience|Depression||Research Area|Neuroscience|Behavioral Neuroscience|Learning & Memory||Research Area|Neuroscience|Pain Research